Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ProMIS Neurosciences Inc. (PMN)

ProMIS reports Q2 2026 net loss of $11.7 million and $53.4 million in cash

Mixed Impact 3 of 5 earnings Written later

ProMIS Neurosciences reported a net loss of $11.7 million, or $1.28 per share, for the quarter ended June 30, 2026, up from a $10.1 million loss a year earlier. Cash and short-term investments were $53.4 million, which the company says will fund operations through 2027, past the expected first quarter 2027 topline readout from its PRECISE-AD trial. Per-share loss narrowed mainly because of more weighted-average shares after a January 2026 financing.

Key points

  • Q2 2026 net loss was $11.7 million ($1.28 per share), versus $10.1 million ($7.26 per share) in Q2 2025
  • Cash and short-term investments were $53.4 million at June 30, 2026, up from $6.1 million at December 31, 2025
  • The increase reflects $70.1 million in net proceeds from a January 2026 private placement, in which certain directors and management participated
  • Unblinded 12-month PRECISE-AD topline data is expected in the first quarter of 2027

The filing

CompanyProMIS Neurosciences Inc. (PMN)
Form8-K, current report
Filed with the SECAug 13, 2026, 4:07 PM ET
Accession number0001104659-26-095905

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.